Benefits
Cholestasis / Liver Support
TUDCA (and parent compound UDCA — Actigall, Urso) is established prescription treatment for primary biliary cholangitis (PBC). TUDCA replaces toxic bile acids with hydrophilic versions, reduces hepatocyte injury. Modest evidence in non-prescription supplemental use for general liver support and elevated liver enzymes.
ER Stress Reduction (Endoplasmic Reticulum Stress)
TUDCA reduces ER stress and unfolded protein response — relevant for diabetes, neurodegeneration, fatty liver, and ischemia-reperfusion injury. Foundational mechanism distinguishes TUDCA from many liver supplements.
ALS / Neurodegenerative Disease Adjunct (Research)
AMX0035 (Relyvrio®) — TUDCA + sodium phenylbutyrate combination — was approved by FDA in 2022 for ALS based on CENTAUR trial showing slower disease progression. WITHDRAWN FROM MARKET 2024 after Phase 3 confirmatory trial failed to show benefit. TUDCA's neuroprotective mechanism remains scientifically interesting; clinical translation for ALS is questionable.
Eye Health / Retinitis Pigmentosa Research
Animal models of retinitis pigmentosa show TUDCA reduces retinal cell apoptosis. 'Bear bile' traditionally used in TCM for eye conditions — modern TUDCA represents this lineage.
Gallstone Dissolution (Modest)
Same mechanism as parent compound UDCA which is established gallstone dissolution therapy. TUDCA may provide similar effects; UDCA has stronger direct evidence.
Mechanism of action
Hydrophilic Bile Acid Substitution
TUDCA is a hydrophilic (water-soluble) bile acid — when added to the bile acid pool, it dilutes more toxic hydrophobic bile acids. Reduces hepatocyte membrane injury and apoptosis from bile acid toxicity. Foundational mechanism for cholestasis applications.
ER Stress / UPR Modulation
Reduces endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) — pathways activated in many disease states (diabetes, neurodegeneration, NAFLD). Acts as 'chemical chaperone' supporting protein folding.
Anti-Apoptotic Activity
Inhibits mitochondrial pathway of apoptosis — protects various cell types (hepatocytes, neurons, retinal cells) from programmed cell death. Mechanism involves Bcl-2 family modulation and caspase inhibition.
Anti-Inflammatory Effects
Reduces pro-inflammatory cytokine production via NF-κB modulation and other pathways. Contributes to liver-protective effects.
Clinical trials
Phase 2 RCT of AMX0035 (TUDCA 1 g + sodium phenylbutyrate 3 g, twice daily) vs placebo in 137 ALS patients for 24 weeks.
137 ALS patients.
Significantly slower disease progression (ALSFRS-R) vs placebo. Generated FDA approval (2022). HOWEVER, Phase 3 confirmatory PHOENIX trial (2024) FAILED to show benefit; product withdrawn from market 2024.
Multiple trials of UDCA (and TUDCA) for PBC over decades.
PBC patients.
Established prescription treatment; significantly improves liver enzymes, may slow disease progression. UDCA stronger evidence base; TUDCA used similarly in some countries.
About this ingredient
TUDCA (Tauroursodeoxycholic Acid) is the TAURINE-CONJUGATED form of UDCA (ursodeoxycholic acid) — a hydrophilic bile acid found naturally in small amounts in human bile (predominantly via gut microbiome metabolism of primary bile acids). Used in TRADITIONAL CHINESE MEDICINE for over 3,000 years as 'BEAR BILE' (xiong dan) — historically harvested from Asian black bears (now an animal welfare and conservation crisis); modern TUDCA is SYNTHESIZED, not animal-derived (reputable products specify synthetic source). RELATIONSHIP TO UDCA: parent compound UDCA (ursodiol, brand names Actigall, Urso) is established prescription medication for primary biliary cholangitis (PBC), gallstone dissolution, and other indications since 1980s. TUDCA is the taurine-conjugated form — better water solubility and theoretically improved absorption.
EVIDENCE-BASED USES: (1) PRIMARY BILIARY CHOLANGITIS — UDCA is established treatment; TUDCA used similarly in some countries; (2) GENERAL LIVER SUPPORT — modest evidence; (3) ER STRESS REDUCTION — research interest; (4) Gallstone dissolution (UDCA stronger evidence); (5) Neurodegenerative disease research — ALS adjunct (failed Phase 3).
CRITICAL CAUTIONS: (1) AMX0035 / RELYVRIO® WITHDRAWAL — TUDCA + sodium phenylbutyrate combination was FDA-approved for ALS in 2022 based on Phase 2 CENTAUR trial; Phase 3 PHOENIX trial in 2024 FAILED to confirm benefit; product VOLUNTARILY WITHDRAWN from market April 2024; TUDCA's role in ALS is now uncertain — caution about expecting benefit based on original approval; (2) BILE DUCT OBSTRUCTION — bile acids contraindicated; medical supervision required; (3) PREGNANCY/LACTATION — UDCA is used in pregnancy for cholestasis of pregnancy under medical supervision; supplemental TUDCA limited data; consult; (4) PRESCRIPTION VS SUPPLEMENT — for PBC, pharmaceutical UDCA (ursodiol) has stronger evidence and FDA approval; TUDCA supplementation is reasonable as adjunct or for general liver support, but NOT substitute for prescribed UDCA in PBC; (5) BEAR CONSERVATION — never purchase animal-derived 'bear bile' products; bile bear farming is animal welfare disaster and contributes to bear poaching; verify synthetic source; (6) DOSE — 250-1,750 mg/day for general liver support; ALS research used 1 g BID combined with sodium phenylbutyrate; (7) BIOAVAILABILITY — taurine conjugation theoretically improves absorption vs UDCA; may allow lower doses for similar effect; (8) SOURCING — quality varies dramatically; reputable brands provide synthesis details and purity testing; (9) CHOLESTASIS OF PREGNANCY — UDCA is established treatment; supplementation for THIS specific indication should be UDCA prescription, not OTC TUDCA, under obstetrician supervision; (10) FATTY LIVER (NAFLD/NASH) — TUDCA's mechanisms are theoretically beneficial; clinical evidence emerging but not yet established; comprehensive lifestyle approach remains foundational; (11) BIOFLAVONOIDS / GENERAL LIVER SUPPORT — for non-pathological liver support, TUDCA is one of several evidence-supported options (alongside milk thistle, NAC, alpha-lipoic acid); not necessarily superior; (12) ER STRESS APPLICATIONS — emerging research area in diabetes, NAFLD, neurodegeneration; preclinical interesting; clinical translation pending.